Home » Stocks » SYNH

Syneos Health, Inc. (SYNH)

Stock Price: $82.64 USD -0.18 (-0.22%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Market Cap 8.67B
Revenue (ttm) 4.46B
Net Income (ttm) 197.94M
Shares Out 104.27M
EPS (ttm) 1.88
PE Ratio 43.96
Forward PE 19.23
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $82.64
Previous Close $82.82
Change ($) -0.18
Change (%) -0.22%
Day's Open 83.06
Day's Range 82.34 - 84.01
Day's Volume 1,220,436
52-Week Range 50.26 - 89.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MORRISVILLE, N.C., May 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today annou...

6 days ago - GlobeNewsWire

MORRISVILLE, N.C., May 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today annou...

1 week ago - GlobeNewsWire

Syneos Health (SYNH) registers sales uptick in its Clinical Solutions business on the back of favorable acquisition impacts and increased project start-up activities.

1 week ago - Zacks Investment Research

MORRISVILLE, N.C., April 30, 2021 (GLOBE NEWSWIRE) -- The Illingworth Research Group, a Syneos Health® company, has been recognized with a 2021 Queen's Award for Enterprise for International Trade. Illi...

1 week ago - GlobeNewsWire

Syneos Health (SYNH) delivered earnings and revenue surprises of 6.76% and 1.83%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Shares of Syneos Health (NASDAQ:SYNH) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share increased 16.18% over the past year to $0.79, which beat the estimat...

1 week ago - Benzinga

Highlights

1 week ago - GlobeNewsWire

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

MORRISVILLE, N.C., April 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its first quarter 2021 financial resu...

1 month ago - GlobeNewsWire

Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery of its operating segments and strategic partnerships.

1 month ago - Zacks Investment Research

Syneos Health (SYNH) new partnership will extend the company's mission to boost research and enable universal patient and provider access with clinical research services.

1 month ago - Zacks Investment Research

Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

MORRISVILLE, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining ...

2 months ago - GlobeNewsWire

MORRISVILLE, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining ...

2 months ago - GlobeNewsWire

Strategic Partnership Optimizes Integration for EHR Data and Delivers Remote Source Data Review Strategic Partnership Optimizes Integration for EHR Data and Delivers Remote Source Data Review

2 months ago - GlobeNewsWire

Seasoned Talent to Drive Expansion of Solutions at the Intersection of Value and Policy Seasoned Talent to Drive Expansion of Solutions at the Intersection of Value and Policy

2 months ago - GlobeNewsWire

Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.

2 months ago - Zacks Investment Research

Syneos Health (SYNH) delivered earnings and revenue surprises of 0.00% and 0.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Syneos Health (NASDAQ:SYNH) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share rose 7.77% year over year to $1.11, which beat the estimate of $1.10.

2 months ago - Benzinga

Shared Commitment to Change, New Prescriber Realities, Model Evolution and Engagement Transformation Expected to be Critical Drivers Shared Commitment to Change, New Prescriber Realities, Model Evolutio...

2 months ago - GlobeNewsWire

MORRISVILLE, N.C., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and full year 2020 ...

3 months ago - GlobeNewsWire

MORRISVILLE, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and...

4 months ago - GlobeNewsWire

Syneos Health (SYNH) is currently working on bringing greater flexibility to each customer study, based on data, people, process and technology.

4 months ago - Zacks Investment Research

Acquisition Enhances Company's Decentralized Solutions Offering by Strengthening Patient Focus Acquisition Enhances Company's Decentralized Solutions Offering by Strengthening Patient Focus

4 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Syneos Health (SYNH).

4 months ago - Zacks Investment Research

Let's see if Syneos Health (SYNH) stock is a good choice for value-oriented investors right now from multiple angles.

4 months ago - Zacks Investment Research

Syneos Health reduced its 2020 guidance but boosted its EBITDA margin guidance.

5 months ago - Seeking Alpha

GREENWICH, Conn.--(BUSINESS WIRE)--Amulet Capital Partners Completes the Sale of Synteract to Syneos Health

5 months ago - Business Wire

MORRISVILLE, N.C., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it has completed the previousl...

5 months ago - GlobeNewsWire

Unique Product Development Model Delivers Accelerated Growth

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass. & MORRISVILLE, N.C.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company developing next-generation infectious disease and immuno-oncology vac...

Other stocks mentioned: VBIV
5 months ago - Business Wire

Combination Offers Customers Access to Largest U.S. Oncology Real World Data Source and Best-in-Class Product Development Expertise for Faster, Smarter and More Patient-Centric Clinical Trials Combinati...

5 months ago - GlobeNewsWire

MORRISVILLE, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a...

5 months ago - GlobeNewsWire

MORRISVILLE, N.C., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a...

5 months ago - GlobeNewsWire

Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery in the Clinical Solutions segment and strategic partnerships.

5 months ago - Zacks Investment Research

MORRISVILLE, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a...

5 months ago - GlobeNewsWire

MORRISVILLE, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a...

5 months ago - GlobeNewsWire

MORRISVILLE, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a...

5 months ago - GlobeNewsWire

MORRISVILLE, N.C., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Larry A. Pickett,...

5 months ago - GlobeNewsWire

MORRISVILLE, N.C., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and...

5 months ago - GlobeNewsWire

Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.

6 months ago - Zacks Investment Research

MORRISVILLE, N.C., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and...

6 months ago - GlobeNewsWire

Syneos Health, Inc. (SYNH) CEO Alistair Macdonald on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

  Shares of Syneos Health (NASDAQ:SYNH) moved higher by 3.2% in pre-market trading after the company reported Q3 results.

6 months ago - Benzinga

Syneos Health (SYNH) delivered earnings and revenue surprises of 15.56% and -1.92%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

GREENWICH, Conn.--(BUSINESS WIRE)--Amulet Capital Backed Synteract To Be Acquired by Syneos Health

6 months ago - Business Wire

Highlights

6 months ago - GlobeNewsWire

Combination Enhances Syneos Health's Industry-Leading Position Across Fast-Growing Small to Mid-Sized Category Combination Enhances Syneos Health's Industry-Leading Position Across Fast-Growing Small to...

6 months ago - GlobeNewsWire

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

About SYNH

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist c... [Read more...]

Industry
Diagnostics & Research
IPO Date
Nov 7, 2014
CEO
Alistair Macdonald
Employees
24,310
Stock Exchange
NASDAQ
Ticker Symbol
SYNH
Full Company Profile

Financial Performance

In 2020, Syneos Health's revenue was $4.42 billion, a decrease of -5.56% compared to the previous year's $4.68 billion. Earnings were $192.79 million, an increase of 46.88%.

Financial Statements

Analyst Forecasts

According to 14 analysts, the average rating for Syneos Health stock is "Buy." The 12-month stock price forecast is 94.55, which is an increase of 14.41% from the latest price.

Price Target
$94.55
(14.41% upside)
Analyst Consensus: Buy